Literature DB >> 28940597

Muscle volume loss a prognostic factor for death in liver cirrhosis patients and special relationship to portal hypertension.

Atsushi Hiraoka1, Shogo Kitahata1, Hirofumi Izumoto1, Hidetaro Ueki1, Toshihiko Aibiki1, Tomonari Okudaira1, Yuji Miyamoto1, Hiroka Yamago1, Ryuichiro Iwasaki1, Hideomi Tomida1, Kenichiro Mori1, Masato Kishida1, Eiji Tsubouchi1, Hideki Miyata1, Tomoyuki Ninomiya1, Masashi Hirooka2, Yoshio Tokumoto2, Masanori Abe2, Bunzo Matsuura2, Yoichi Hiasa2, Kojiro Michitaka1.   

Abstract

AIM: We examined the prognosis of liver cirrhosis (LC) patients with and without portal hypertension (PHT) and muscle volume loss (MVL).
METHODS: From 2006 to 2016, 346 LC outpatients (PHT/non-PHT = 173/173) were enrolled (median age, 69 years; men / women, 204/142; Child-Pugh A / B, 230/116; and presence of MVL 15.6% in each group) after propensity matching, following exclusion of those with hepatocellular carcinoma (HCC) beyond the Milan criteria and Child-Pugh C. Portal hypertension was defined as positive for significant esophagogastric varices; MVL was diagnosed based on a previously reported index using CT imaging. Overall survival rate (OSR) was evaluated from the viewpoints of PHT and MVL.
RESULTS: There were no significant differences in clinical background (age, gender, etiology, presence of HCC [within Milan criteria], or Child-Pugh class) between the groups. Although there was no significant difference regarding OSR between patients with and without MVL in the non-PHT group (P = 0.076, Holm's method), the OSR of patients with MVL in the PHT group was lower compared to those without MVL in both groups (P = 0.017 and P = 0.012, respectively, Holm's method). As a result, the OSR of patients with MVL (n = 54) was lower than the other patients (n = 292) (3- and 5-year OSR, 69.0% vs. 86.4% and 35.8% vs. 74.1%, respectively; P < 0.001). Multivariate Cox hazard analysis showed that positive for HCC (hazard ratio [HR], 2.028; 95% confidence interval [CI], 1.189-3.460; P = 0.009) and positive for MVL (HR, 2.768; 95% CI, 1.575-4.863; P < 0.001) were significant independent prognostic factors for death.
CONCLUSION: Muscle volume loss and HCC, but not PHT, were found to be independent prognostic factors for death in LC patients.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  esophagogastric varices; liver cirrhosis; muscle volume loss; portal hypertension; prognosis

Year:  2017        PMID: 28940597     DOI: 10.1111/hepr.12984

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  5 in total

1.  Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.

Authors:  Atsushi Hiraoka; Masaya Kato; Kaori Marui; Taisei Murakami; Kei Onishi; Tomoko Adachi; Junko Matsuoka; Hidetaro Ueki; Takeaki Yoshino; Miho Tsuruta; Toshihiko Aibiki; Tomonari Okudaira; Taira Kuroda; Ryuichiro Iwasaki; Yoshifumi Suga; Hideki Miyata; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Kojiro Michitaka; Yoichi Hiasa
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

2.  Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Koichi Takaguchi; Masanori Atsukawa; Ei Itobayashi; Kunihiko Tsuji; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Hiroshi Shibata; Toru Ishikawa; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Norio Itokawa; Michitaka Imai; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

3.  Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test.

Authors:  Atsushi Hiraoka; Hirofumi Izumoto; Hidetaro Ueki; Takeaki Yoshino; Toshihiko Aibiki; Tomonari Okudaira; Hiroka Yamago; Yoshifumi Suga; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Hideki Miyata; Eiji Tsubouchi; Masato Kishida; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Yoichi Hiasa; Kojiro Michitaka
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-02-21       Impact factor: 12.910

4.  Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.

Authors:  Ryotaro Sakamori; Ryoko Yamada; Kazuma Shinkai; Akira Doi; Yuki Tahata; Minoru Shigekawa; Takahiro Kodama; Hayato Hikita; Tomomi Yamada; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Intern Med       Date:  2021-03-01       Impact factor: 1.271

5.  Metabolomics of Artichoke Bud Extract in Spontaneously Hypertensive Rats.

Authors:  Zhi-Bin Wang; Shi-Long Jiang; Shao-Bo Liu; Jing-Bo Peng; Shuo Hu; Xu Wang; Wei Zhuo; Tong Liu; Ji-Wei Guo; Hong-Hao Zhou; Zhi-Quan Yang; Xiao-Yuan Mao; Zhao-Qian Liu
Journal:  ACS Omega       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.